Phil Taylor, Author at - Page 3 of 272

Infected female deer tick on hairy human skin. Ixodes ricinus. Dangerous mite detail. Acarus. Infectious borreliosis

Pfizer has acquired an 8.1% stake in French vaccines developer Valneva at a cost of €90.5 million (around

Pfizer takes stake in French Lyme disease jab partner Valneva

https://pharmaphorum.com/news/pfizer-takes-stake-in-french-lyme-disease-jab-partner-valneva/

News/ News/ News/ News/ Oncology/ R&D/ Sales and Marketing

Is Merck planning a $30bn-plus move for Seagen?

Phil Taylor M&A, Merck & Co, Oncology, Seagen 0 Comment

Speculation that Merck & Co may be preparing a $30 billion takeover bid for Seagen – bolstering its

Is Merck planning a $30bn-plus move for Seagen?

https://pharmaphorum.com/news/is-merck-planning-a-30bn-plus-move-for-seagen/

Market Access/ News/ News/ News/ News/ Oncology/ Patients

Lilly’s Verzenios gets NICE blessing for early-stage breast cancer

Phil Taylor breast cancer, Eli Lilly, HEOR, NHS, NICE, Oncology, Verzenio 0 Comment

Thousands more people with breast cancer in England look set to be eligible for routine treatment with Eli

Lilly’s Verzenios gets NICE blessing for early-stage breast cancer

https://pharmaphorum.com/news/lillys-verzenios-gets-nice-blessing-for-early-stage-breast-cancer/

Market Access/ News/ News

FDA panel turns down Acadia’s Nuplazid for Alzheimer’s psychosis

Phil Taylor Acadia Pharmaceuticals, Alzheimer's disease, fda, Nuplazid, psychosis 0 Comment

Acadia Pharma’s attempts to extend the indications of its Nuplazid drug in the US to include Alzheimer’s disease-related

FDA panel turns down Acadia’s Nuplazid for Alzheimer’s psychosis

https://pharmaphorum.com/news/fda-panel-turns-down-acadias-nuplazid-for-alzheimers-psychosis/

Digital/ News/ News

Canadian comms giant Telus buys digital health player LifeWorks

Phil Taylor digital, digital health, LifeWorks, M&A, mental health, telehealth, telemedicine, Telus Health 0 Comment

Canadian wireless network carrier Telus has agreed to a C$2.9 billion ($2.2 billion) deal to acquire LifeWorks, a

Canadian comms giant Telus buys digital health player LifeWorks

https://pharmaphorum.com/news/canadian-comms-giant-telus-buys-digital-health-player-lifeworks/

News/ News/ Sales and Marketing

Rumour mill says AstraZeneca may be eyeing a takeover of Mereo

Phil Taylor AstraZeneca, M&A, Mereo Biopharma 0 Comment

AstraZeneca is rumoured to be considering a bid to take control of its longstanding partner Mereo BioPharma, according

Rumour mill says AstraZeneca may be eyeing a takeover of Mereo

https://pharmaphorum.com/news/rumour-mill-says-astrazeneca-may-be-eyeing-a-takeover-of-mereo/

News/ News/ News/ Patients/ R&D

Pharmacy chain Walgreens plans to disrupt clinical trial sector

Phil Taylor clinical trials, CVS, decentralised clinical trials, diversity, patients, Walgreens 0 Comment

Walgreens is the latest US retail pharmacy giant to have a go at disrupting the clinical trials industry,

Pharmacy chain Walgreens plans to disrupt clinical trial sector

https://pharmaphorum.com/news/pharmacy-chain-walgreens-plans-to-disrupt-clinical-trial-sector/

News/ News/ News/ Oncology/ R&D

Decentralised trials gaining ground in oncology, says report

Phil Taylor biosensors, clinical research, clinical trials, decentralised trials, Oncology, Science 37, wearables 0 Comment

A survey of clinical research executives working in the cancer arena has found that nearly three quarters of

Decentralised trials gaining ground in oncology, says report

https://pharmaphorum.com/news/decentralised-trials-gaining-ground-in-oncology-says-report/

News/ News/ R&D

Biogen waves bye to $217m ALS partnership with Karyopharm

Phil Taylor ALS, Biogen, Karyopharm, neurology, partnering 0 Comment

Biogen has ducked out of a four-year-old collaboration with Karyopharm on a drug candidate for the neurodegenerative disease

Biogen waves bye to $217m ALS partnership with Karyopharm

https://pharmaphorum.com/news/biogen-says-bye-to-217m-als-partnership-with-karyopharm/

Trending

About Phil Taylor

Posts by Phil Taylor:

Pfizer takes stake in French Lyme disease jab partner Valneva

Is Merck planning a $30bn-plus move for Seagen?

Lilly’s Verzenios gets NICE blessing for early-stage breast cancer

FDA panel turns down Acadia’s Nuplazid for Alzheimer’s psychosis

Canadian comms giant Telus buys digital health player LifeWorks

Rumour mill says AstraZeneca may be eyeing a takeover of Mereo

Pharmacy chain Walgreens plans to disrupt clinical trial sector

Decentralised trials gaining ground in oncology, says report

Biogen waves bye to $217m ALS partnership with Karyopharm

Trending

About Phil Taylor

Posts by Phil Taylor:

Login